ARGX – argenx SE
argenx SEARGX
$571.85Name : argenx SE
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $34,877,644,800.00
EPSttm : 12.8
argenx SE
$571.85
3.09%$18.21Float Short %
3.69
Margin Of Safety %
Put/Call OI Ratio
0.44
EPS Next Q Diff
0.88
EPS Last/This Y
EPS This/Next Y
8.04
Price
589.19
Target Price
745.99
Analyst Recom
1.33
Performance Q
-4.06
Relative Volume
2.18
Beta
0.58
Ticker: ARGX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | ARGX | 637.57 | 0.52 | 0.17 | 8050 |
| 2025-03-06 | ARGX | 613.24 | 0.52 | 0.24 | 8052 |
| 2025-03-07 | ARGX | 590 | 0.51 | 0.95 | 8148 |
| 2025-03-10 | ARGX | 570.55 | 0.50 | 0.23 | 8125 |
| 2025-03-11 | ARGX | 580.71 | 0.45 | 2.17 | 8216 |
| 2025-03-12 | ARGX | 590.34 | 0.44 | 38.80 | 8177 |
| 2025-03-13 | ARGX | 581.46 | 0.46 | 3.21 | 8326 |
| 2025-03-14 | ARGX | 604.98 | 0.48 | 0.23 | 8527 |
| 2025-03-17 | ARGX | 614.39 | 0.47 | 22.71 | 8567 |
| 2025-03-18 | ARGX | 611.67 | 0.48 | 1.37 | 8515 |
| 2025-03-19 | ARGX | 619.94 | 0.48 | 0.27 | 8549 |
| 2025-03-20 | ARGX | 614.04 | 0.48 | 0.13 | 8633 |
| 2025-03-21 | ARGX | 614.58 | 0.45 | 6.05 | 8749 |
| 2025-03-24 | ARGX | 608.4 | 0.39 | 0.42 | 5846 |
| 2025-03-25 | ARGX | 604.69 | 0.39 | 0.00 | 5890 |
| 2025-03-26 | ARGX | 584.38 | 0.39 | 0.55 | 5906 |
| 2025-03-27 | ARGX | 594.12 | 0.39 | 0.00 | 5990 |
| 2025-03-28 | ARGX | 589.44 | 0.39 | 2.21 | 5990 |
| 2025-03-31 | ARGX | 591.48 | 0.39 | 2.22 | 5988 |
| 2025-04-01 | ARGX | 565.95 | 0.39 | 0.34 | 6068 |
| 2025-04-02 | ARGX | 582.6 | 0.44 | 1.33 | 6553 |
| 2025-04-03 | ARGX | 589.28 | 0.44 | 0.09 | 6561 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | ARGX | 636.35 | 339.1 | 541.2 | 12.17 |
| 2025-03-06 | ARGX | 613.16 | 303.1 | 363.0 | 11.19 |
| 2025-03-07 | ARGX | 593.02 | 303.1 | 358.7 | 12.06 |
| 2025-03-10 | ARGX | 570.66 | 303.1 | 365.3 | 12.06 |
| 2025-03-11 | ARGX | 580.57 | 303.1 | 382.5 | 12.06 |
| 2025-03-12 | ARGX | 590.85 | 303.1 | 387.9 | 12.06 |
| 2025-03-13 | ARGX | 581.68 | 303.1 | 387.4 | 12.06 |
| 2025-03-14 | ARGX | 604.96 | 303.1 | 388.4 | 12.06 |
| 2025-03-17 | ARGX | 614.19 | 303.1 | 397.3 | 12.06 |
| 2025-03-18 | ARGX | 612.03 | 300.8 | 374.0 | 12.08 |
| 2025-03-19 | ARGX | 619.97 | 300.8 | 376.8 | 12.08 |
| 2025-03-20 | ARGX | 613.04 | 300.8 | 369.8 | 12.45 |
| 2025-03-21 | ARGX | 614.65 | 298.9 | 532.0 | 12.39 |
| 2025-03-24 | ARGX | 607.95 | 298.9 | 222.0 | 12.39 |
| 2025-03-25 | ARGX | 605.52 | 298.9 | 219.9 | 12.40 |
| 2025-03-26 | ARGX | 583.66 | 298.9 | 209.2 | 12.40 |
| 2025-03-27 | ARGX | 594.02 | 298.9 | 218.6 | 12.40 |
| 2025-03-28 | ARGX | 589.15 | 298.9 | 223.6 | 12.40 |
| 2025-03-31 | ARGX | 592.31 | 298.9 | 221.1 | 12.40 |
| 2025-04-01 | ARGX | 567.09 | 298.9 | 213.0 | 12.40 |
| 2025-04-02 | ARGX | 583.62 | 298.9 | 212.2 | 12.40 |
| 2025-04-03 | ARGX | 589.19 | 298.9 | 219.7 | 12.40 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | ARGX | 0.00 | -2.16 | 3.40 |
| 2025-03-06 | ARGX | 0.00 | -2.16 | 3.40 |
| 2025-03-07 | ARGX | 0.00 | -2.16 | 3.40 |
| 2025-03-10 | ARGX | 0.00 | -2.54 | 3.40 |
| 2025-03-11 | ARGX | 0.00 | -2.54 | 3.40 |
| 2025-03-12 | ARGX | 0.00 | -2.54 | 3.30 |
| 2025-03-13 | ARGX | 0.00 | -2.54 | 3.30 |
| 2025-03-14 | ARGX | 0.00 | -2.54 | 3.30 |
| 2025-03-17 | ARGX | 0.00 | -1.87 | 3.30 |
| 2025-03-18 | ARGX | 0.00 | -1.87 | 3.30 |
| 2025-03-19 | ARGX | 0.00 | -1.87 | 3.30 |
| 2025-03-20 | ARGX | 0.00 | -1.87 | 3.30 |
| 2025-03-21 | ARGX | 0.00 | -1.87 | 3.30 |
| 2025-03-24 | ARGX | 0.00 | -1.88 | 3.30 |
| 2025-03-25 | ARGX | 0.00 | -1.88 | 3.30 |
| 2025-03-26 | ARGX | 0.00 | -1.88 | 3.69 |
| 2025-03-27 | ARGX | 0.00 | -1.88 | 3.69 |
| 2025-03-28 | ARGX | 0.00 | -1.88 | 3.69 |
| 2025-03-31 | ARGX | 0.00 | -8.55 | 3.69 |
| 2025-04-01 | ARGX | 0.00 | -8.55 | 3.69 |
| 2025-04-02 | ARGX | 0.00 | -8.55 | 3.69 |
| 2025-04-03 | ARGX | 0.00 | -8.55 | 3.69 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.58
Avg. EPS Est. Current Quarter
1.92
Avg. EPS Est. Next Quarter
2.46
Insider Transactions
Institutional Transactions
-8.55
Beta
0.58
Average Sales Estimate Current Quarter
748
Average Sales Estimate Next Quarter
815
Fair Value
Quality Score
100
Growth Score
56
Sentiment Score
23
Actual DrawDown %
13.1
Max Drawdown 5-Year %
-38.2
Target Price
745.99
P/E
46.26
Forward P/E
30.06
PEG
1.61
P/S
16.4
P/B
6.52
P/Free Cash Flow
1325.4
EPS
12.76
Average EPS Est. Cur. Y
12.4
EPS Next Y. (Est.)
20.44
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
38.03
Relative Volume
2.18
Return on Equity vs Sector %
-11.3
Return on Equity vs Industry %
1.6
EPS 1 7Days Diff
0.3
EPS 1 30Days Diff
2.51
EBIT Estimation
219.7
argenx SESector: Healthcare
Industry: Biotechnology
Employees: 1599
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren's disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy. In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
stock quote shares ARGX – argenx SE Stock Price stock today
news today ARGX – argenx SE stock forecast ,stock prediction 2023 2024 2025
marketwatch ARGX – argenx SE yahoo finance google finance
stock history ARGX – argenx SE invest stock market
stock prices ARGX premarket after hours
ticker ARGX fair value insiders trading